Posts

Showing posts with the label Pruritus Therapeutics Market Size

Pruritus Therapeutics Market To Expand Industry Growth At USD 16.38 Billion By 2025

Image
  San Francisco, 25 April 2023:  The Report   Pruritus Therapeutics Market  By Product (Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, Pipeline, Unmet Needs), By Disease Type (Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria) Analysis And Segment Forecasts To 2025 The global pruritus therapeutics market is expected to reach USD 16.38 Billion by 2025, according to a new study by Grand View Research, Inc. Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast period. The introduction of new products based on scientific mechanistic understanding such as the identification of new T-cell subsets, particularly Th17, and Th22 and the patent expiration of PROTOPIC (tacrolimus) is expected to open up new avenues for manufacturers to capitalize on over the forecast period.  Corticosteroids w...

Pruritus Therapeutics Market Size Expected To Reach USD 16.38 Billion By 2025 : Grand View Research Inc.

San Francisco, 28 August 2019:   The Report   Pruritus Therapeutics Market   By Product (Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, Pipeline, Unmet Needs), By Disease Type (Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria) Analysis And Segment Forecasts To 2025 Global pruritus therapeutics market is expected to reach USD 16.38 Billion by 2025, according to a new study by Grand View Research, Inc. Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis and urticaria is expected to drive market growth during the forecast period. Introduction of new products based on scientific mechanistic understanding such as the identification of new T-cell subsets, particularly Th17, and Th22 and the patent expiration of PROTOPIC (tacrolimus) is expected to open up new avenues for manufacturers to capitalize on over the forecast period. Corticosteroids were the leadin...